Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy.
Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy.
复制标题
DOI：
10.3389/fimmu.2022.1074906
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
本初步研究（NCT03958097;）旨在评估PD-1抗体联合自体NK细胞治疗一线铂基化疗失败的IIIB/IIIC或IV期非小细胞肺癌（NSCLC）患者的疗效和安全性。所有患者每3周接受sintilmab 200mg和3×109 NK细胞治疗。20例患者入组，中位随访时间为22.6个月。中位PFS为11.6个月，ORR为45%。中位OS为17.7个月，6个月OS为95.0%，12个月OS为80.0%。未观察到意外不良事件。2例患者报告了3级不良事件（高甘油三酯血症、中性粒细胞减少症和肌酸激酶升高）。自体NK细胞未给ICI治疗增加额外的不良事件。自体NK + sintilmab在一线治疗失败的晚期驱动突变阴性NSCLC中显示出有希望的抗肿瘤活性和可接受的安全性。
This pilot study (NCT03958097; ) was aimed to evaluate the efficacy and safety of PD-1 antibody combined autologous NK cells in the treatment of patients with stage IIIB/IIIC or IV non-small-cell lung cancer (NSCLC) who failed the first-line platinum-based chemotherapy. All patients received both sintilimab 200mg and 3×109 NK cells every 3 weeks. 20 patients were enrolled, median follow up time was 22.6 months. The median PFS was 11.6 months, ORR was 45%. Median OS was 17.7 months, 6-month OS rate and 12-month OS rate was 95.0% and 80.0%. Unexpected adverse events were not observed. 2 patients reported grade 3 adverse events (hypertriglyceridemia, neutropenia and increased creatine kinase). The autologous NK cells did not add extra adverse events to the ICI treatment. Autologous NK plus sintilimab showed promising antitumor activity and an acceptable safety profile in advanced driven-mutation negative NSCLC who failed on the first line treatment.
影响因子：
4.7
作者：
Zhai X;Jing X;Li J;Tian Y;Xu S;Wang M;Zhu H
通讯作者：
Zhu H